Concert Looks To Phase III In Alopecia Areata, Ahead Of Pfizer’s JAK Inhibitor
Concert believes its deuterated form of ruxolitinib has a better overall profile in alopecia areata than Pfizer’s JAK3 inhibitor. The company is planning to meet with the FDA to plan a Phase III program early in 2020.
You may also be interested in...
The latest breakthrough therapy designation announcements from the Pink Sheet’s US FDA Performance Tracker
Blueprint and Zymeworks raise $300m-plus in follow-on offerings. Also, Arcutis, Black Diamond and Annovis bring the 2020 US IPO count to four; Spring Bank, Surface Oncology and Decibel reveal strategic shifts; and Harmony’s $200m in venture debt leads recent VC deals.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.